Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus NAPROXEN SODIUM.
DYLOJECT vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID